Orchid Pharma–Dhanuka Merger Creates ₹1,500 Cr Pharma Giant

$ORCHPHARMA Key Highlights Merger Approval: NCLT clears merger of Dhanuka Laboratories with Orchid Pharma. Revenue Potential: Combined entity expected to generate ₹1,400–1,500 crore revenue. EBITDA Outlook: EBITDA projected at ₹200–250 crore. Synergies: Operational efficiencies, cost savings, and stronger market presence. 📊 Financial Snapshot (Post-Merger Estimates) Metric Value Implication Revenue ₹1,400–1,500 Cr Strong topline growth. EBITDA ₹200–250 Cr Margin expansion potential. EBITDA Margin ~15–17% Healthy profitability. Debt Position Moderate Manageable leverage post-merger. ROCE ~12–14% Improved capital efficiency. ROE ~10–12% Stronger shareholder returns. ⚡ Growth Drivers Integrated operations → cost savings and efficiency. Expanded product portfolio → stronger domestic & export presence. Synergies in R&D and manufacturing. Enhanced scale → better bargaining power and market positioning. ⚠️ Risks Integration challenges between Orchid and Dhanuka. Regulatory hurdles in pharma approvals. Competitive pressures from larger peers (Sun Pharma, Dr. Reddy’s, Cipla). The merger positions Orchid Pharma as a mid-sized integrated pharma player with stronger fundamentals, improved margins, and enhanced market presence.